Skip to main content
. 2017 Jul 6;8(38):64407–64416. doi: 10.18632/oncotarget.19041

Table 2. Diagnostic performance, design, and quality of included studies.

Author (Ref) Cases Controls TP FP FN TN Design Blinded? QUADAS
Bassarova AV [17] 32 250 32 128 0 122 NA NA 8
Saad RS [18] 20 20 17 0 3 20 R Yes 8
Bhalla R [19] 10 10 10 0 0 10 R NA 9
Hyun TS [20] 11 21 9 0 2 21 R Yes 10
Ordóñez NG [21] 40 123 29 8 11 115 NA NA 11
Chu AY [22] 53 125 51 27 2 98 R NA 12
Müller AM [23] 36 76 22 27 14 49 NA NA 10
Ordóñez NG [24] 40 45 37 6 3 39 NA NA 11
Comin CE [25] 15 40 14 8 1 32 R NA 9
Mimura T [26] 66 66 56 3 10 63 R NA 11
Padgett DM [27] 44 101 38 4 6 97 R NA 12
Amatya VJ [28] 80 80 74 13 6 67 R NA 12
Deniz H [29] 37 36 19 0 18 36 R NA 11
Takeshima Y [30] 45 27 39 7 6 20 R NA 10
Hu YC [31] 36 31 25 2 11 29 R NA 10
Kao SC [32] 80 21 80 0 0 21 R NA 9
Comin CE [33] 75 172 73 25 2 147 R NA 10
Guo Z [8] 43 35 38 24 5 11 R NA 12
Kawai T [34] 22 11 17 3 5 8 P NA 11
Carbone M [5] 10 45 8 10 2 35 R NA 10
Amatya VJ [35] 31 29 22 9 9 20 R Yes 12
Kushitani K [36] 36 38 35 23 1 15 R NA 11

NA: Not available; P: Prospective; R: Retrospective; FN: False negative; FP: False positive; TN: True negative;

TP: True positive; QUADAS: Quality assessment for diagnostic accuracy studies.